Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN

Rice Hall James & Associates LLC increased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 65.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 851,663 shares of the company’s stock after acquiring an additional 336,040 shares during the period. Rice Hall James & Associates LLC owned about 1.04% of Viridian Therapeutics worth $18,379,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Commodore Capital LP boosted its position in Viridian Therapeutics by 35.4% in the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after purchasing an additional 1,275,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares during the last quarter. HighVista Strategies LLC grew its position in Viridian Therapeutics by 168.4% during the second quarter. HighVista Strategies LLC now owns 484,559 shares of the company’s stock valued at $6,774,000 after buying an additional 304,008 shares during the period. Paradigm Biocapital Advisors LP grew its position in Viridian Therapeutics by 15.1% during the first quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock valued at $28,242,000 after buying an additional 275,000 shares during the period. Finally, Exome Asset Management LLC purchased a new stake in Viridian Therapeutics during the first quarter worth about $2,929,000.

Viridian Therapeutics Trading Down 1.2%

NASDAQ:VRDN opened at $31.88 on Friday. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $34.04. The stock’s fifty day moving average price is $28.91 and its two-hundred day moving average price is $21.81. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.28 and a quick ratio of 11.28. The company has a market cap of $3.04 billion, a P/E ratio of -10.56 and a beta of 0.87.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The company had revenue of $70.57 million for the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics’s revenue was up 81993.0% on a year-over-year basis. As a group, analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Insider Activity

In other news, Director Fairmount Funds Management Llc purchased 454,545 shares of the stock in a transaction dated Thursday, October 23rd. The shares were purchased at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the completion of the acquisition, the director owned 3,914,458 shares in the company, valued at $86,118,076. This represents a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.58% of the company’s stock.

Analyst Upgrades and Downgrades

VRDN has been the topic of several research reports. Truist Financial set a $41.00 price objective on shares of Viridian Therapeutics in a research report on Monday, November 24th. William Blair initiated coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. The Goldman Sachs Group reissued a “buy” rating and set a $40.00 price objective on shares of Viridian Therapeutics in a report on Thursday, November 6th. Oppenheimer raised their target price on Viridian Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $61.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $41.75.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.